Note: Descriptions are shown in the official language in which they were submitted.
CA 02339143 2001-O1-31
- ' ~ WO 00/09166 PCTIUS99/18146
-1-
PHOSPHORYLATED POLYMERS AND CONJUGATES THEREOF
l3ackaround of the Invention
The present invention is directed to absorbable; polyesters comprising one or
more monophosphate functionality; a conjugate comprising the foregoing
polyester and a
peptide andlor a bioactive agent; microparticles compri;>ing an absorbable
polyester; a
conjugate comprising the microparticles and a peptide: andlor a bioactive
agent; an
acylated or alkylated polysaccharide having one or more monophosphate
functionality; a
conjugate comprising the acylated or alkylated polysaccharide and a peptide
and/or a
bioactive agent; and pharmaceutical compositions thereof.
Phosphorous-containing heterochain polymers have been cited in the patent and
technical literature in conjunction with {1 ) flame-retardant and/or
hydrophilic polyamides
(Shalaby, S.W., et al., J. Polym. Sci., Polym. Chem. Ed., 12, 2917 (1974);
Shalaby, S.W.,
et al., J. Polym: Sci., Polyrn. Chem. Ed., 13, 669 (1975); Shalaby, S.W., et
al., J. Polym.
Sci.; Polym. Chem. Ed., 14, 2675 (1976); Shalaby, S.W. and McCaig, S., U.S.
Patent No.
5,491,198; Shaiaby, S.W. and Rogers, K.R., U.S. Patent No. 5,558,517); (2}
flame-
retardant polyesters {Heffner, R.E., U.S. Patent No. 4,420,587; Koch, P.J., et
al., J. Appl.
Polym. Sci., 19, 227 (1975}; Japanese Pat. 51-40432}; (3) flame-retardant
polyurethanes
and epoxy resins (German Patent DE 1,292;862, US Pat. 3,321,555}; (4)
thermally stable
polyesters with chain end-groups reacted with phosphonyl thiocyanate (U.S.
Patent No.
3,838,045}; (5) phosphorylated cellulose as a ration-exchanger (DD 286600);
and (6)
phosphorylated polyesters as semiconducting materials (SU, 672878). However,
there is
no disclosure in the art of incorporation of phosphate groups at available
hydroxy end-
group sites of absorbable polyesters, which sites are t~rpically present at
one or two
terminals of the chain. This is not surprising since conditions of chemical
reactions known
for hydroxy group phosphorylation could cause hydrolysis of the highly
reactive
absorbable polyester chains. Meanwhile, there has been great interest in
developing
carboxyl-bearing absorbable polyesters for use in forming conjugates with
bioactive
polypeptides as controlled release systems therefor (Sha~laby, S.W., et al.,
U.S. Patent
No. 5,672,659).
SUBSTITUTE SHEET (RULE 26)
CA 02339143 2001-O1-31
WO 00/09166 PC1'IUS99/1814b
-2-
Therefore, there is an incentive to make directly phosphorylated absorbable
polyesters without significantly causing chain degradation to obtain novel
controlled
release systems.
Summar~~ of the invention
In one aspect, the present invention is directed to an absorbable polyester
with at
least one monophosphate functionality per absorbable polyester chain. A
preferred
embodiment of the immediately foregoing absorbable polyester is where the
polyester
chain comprises one or more monomers selected from the group consisting of L-
lactic
acid, D-lactic acid, DL-lactic acid, malic acid, citric acid, tartaric acid, s-
caprolactone, s-
caproic acid, alkylene oxalate, cycloalkylene oxalate, alkylene succinate, ~i-
hydroxybutyrate, glycolide, glycolic acid, L-lactide, D-lact.ide, DL-lactide,
meso-lactide,
trimethyiene carbonate, p-dioxanone, 1,5-dioxepan-2-one and 1,4-dioxepan-2-one
and
any optically active isomers, racemates, or copolymers thereof. A more
preferred
embodiment of the foregoing invention is where the absorbable polyester
further
comprises one or more polyethylene glycol segments covalently linked to the
polyester. A
further aspect of the foregoing invention, this invention is directed to a
conjugate
comprising the foregoing absorbable polyester and a peptide andlor a bioactive
agent,
where the peptide and bioactive agent have at least one interactive amino
group, wherein
the monophosphate functionality forms a linkage with the amino group. A
preferred
embodiment of the foregoing conjugate is where the peptide is selected from
the group
consisting of p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, H-(3-D-Nal-Cys-
Tyr-D-
Trp-Lys-Val-Cys-Thr-NH2 where the two Cys are bonded by a disulfide bond, N-
hydroxyethyipiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2where
the two
Cys are bonded by a disulfide bond and N-hydroxyethylpiperazinyl-ethylsulfonyl-
Phe-
Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2 where the two Cys are bonded by a disulfide
bond,
or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention is directed to a conjugate comprising
an
absorbable polyester with at least one monophosphate functionality per
absorbable
polyester chain and a peptide andlor a bioactive agent, where the peptide and
bioactive
agent have at least one interactive amino group, vrherein the monophosphate
functionality forms a linkage with the amino group. A preferred conjugate is
wherein the
peptide is selected from the group consisting of p-Glu-Hiis-Trp-Ser-Tyr-D-Trp-
Leu-Arg-
Pro-G1y-NH2, H-(3-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 where the two Cys
are
SUBSTITUTE SHEET (RULE 26'~
CA 02339143 2001-O1-31
WO 00/09166 PG"T/US99/18146
-3-
bonded by a disulfide bond, N-hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-
Trp-Lys-
Abu-Cys-Thr-NH2 where the two Cys are bonded b;y a disulfide bond and N-
hydroxyethyipiperazinyl-ethyisulfonyf-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2
where
the two Cys are bonded by a disulfide bond, or a pharmaceutically acceptable
salt
thereof.
In another aspect, the present invention is directed to a solid absorbable
microparticle which comprises an absorbable polyester with at least one
monophosphate
functionality per absorbable polyester chain and having a surface, wherein
more than one
percent of the monophosphate functionality resides on the surtace of the
absorbable
microparticle. A further aspect of the present invention is a conjugate
comprising the
immediately foregoing absorbable microparticle and a peptide and/or a
bioactive agent,
where the peptide and bioactive agent have at least one ini;eractive amino
group, wherein
the monophosphate functionality on the surface of the absorbable microparticle
forms a
linkage with the amino group. A preferred embodiment of the immediately
foregoing
'( 5 conjugate is the conjugate wherein the peptide is selected ifrom the
group consisting of p-
Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, H-~i-D-N;al-Cys-Tyr-D-Trp-Lys-
Val-Cys-
Thr-NH2 where the two Cys are bonded by a disulfide boind, N-
hydroxyethylpiperazinyl-
acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2 where i:he two Cys are bonded
by a
disulfide bond and N-hydroxyethylpiperazinyl-ethylsulfonyi-Phe-Cys-Tyr-D-Trp-
Lys-Abu-
Cys-Thr-NHZ where the two Cys are bonded by a disult>d~e bond, or a
pharmaceutically
acceptable salt thereof.
In yet another aspect, the present invention is directed to an acylated or
alkylated
absorbable polysaccharide, having one or more terminal monophosphate
functionality
per molecule. A preferred embodiment of the immediately foregoing is where the
absorbable polysaccharide is an acylated gamma-cyclodf:xtrin. A further aspect
of the
foregoing is a conjugate comprising the alkylated or acylated absorbable
polysaccharide
having one or more terminal monophosphate functionality per molecule and a
peptide
andlor a bioactive agent, where the peptide and bioaci:ive agent have at least
one
interactive amino group, wherein the rnonophosphate functionality forms a
linkage with
the amino group. A preferred embodiment of the immediately foregoing conjugate
is a
conjugate where the peptide is selected from the group consisting of p-Glu-His-
Trp-Ser-
Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, H-~3-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
where
the two Cys are bonded by a disulfide bond, N-hydroxyethyfpiperazinyl-acetyl-D-
Phe-
SUBSTITUTE SHEET (RULE 26)
CA 02339143 2001-O1-31
WO 00109166 PCT/US99/18146
-4-
Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2 where the two Cys are bonded by a disulfide
bond
and N-hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-T'yr-D-Trp-L.ys-Abu-Cys-
Thr-NH2
where the two Cys are bonded by a disulfide bond, or a plnarmaceuticaliy
acceptable salt
thereof.
In still another aspect, the present invention is directed to a pharmaceutical
composition comprising one or more of the conjugates described herein.
In a further aspect, the present invention is directed to an absorbable
polymer
with at least one monophosphate functionality for use as an acidic excipient
of a
cyanoacrylate composition.
In another further aspect, the present invention is dlirected to a method for
making
a low melting phosphorylated-hydroxyl-bearing polyester having 1 % to 60%
crystallinity,
which comprises reacting a hydroxyl-bearing polyester with an excess of
pyrophosphoric
acid to yield the phosphorylated-hydroxyl-bearing polyester.
In another further aspect, the present invention is directed to a method for
making
a phosphoryiated-acylated cyclodextrin, which comprises reacting an acylated
cyclodextrin with an excess of pyrophosphoric acid to yield the phosphorylated-
acylated
cyciodextrin.
In another further aspect, the present invention is directed to a method for
making
a phosphorylated-alkylated cyclodextrin, which comprises reacting an aikylated
cyclodextrin with an excess of pyrophosphoric acid to yield the phosphorylated-
aikylated
cyciodextrin.
In another further aspect, the present invention is directed to a method for
making
phosphorylated rnicroparticles, which comprises reacting a hydroxyl-bearing
microparticle
with excess pyrophosphoric acid to yield the phosphoryiated microparticles.
In another further aspect, the present invention is clirected to a method of
making
an acylated-phosphorylated polysaccharide, which comprises reacting a
polysaccharide
concurrently with a heated mixture of pyrophosphoric acid and an acylating
agent to yield
the acylated-phosphorylated polysaccharide. A preferred method of the
foregoing method
is where the polysaccharide is cyclodextrin and the acylating agent is
propionic anhydride
or acetic anhydride. The reaction can be conducted between about room
temperature to
about 100 °C.
In another further aspect, the present invention is directed to a
phosphorylated-
grafted-acyiated cyclodextrin having one or more monophosphate functionality.
SUBSTITUTE SHEET (RULE 26~
CA 02339143 2001-O1-31
WO 00109166 PCTIUS99/I8146
_5_
In another further aspect, the present invention is directed to a method of
preparing phosphorylated-grafted-acyiated cyclodextrin that has been grafted
with a
heterocyclic monomer, including those used for the preparation.of absorbable
polymers,
e.g., lactide, glycofide, trimethylene carbonate andlor s-~caprolactone, which
method
comprises heating a monomer with an acylated cyclodextrin in the presence of a
catalytic
amount of stannous octoate for about 2-24 hours at about 100 °C to 200
°C to form a
reaction mixture comprising grafted-acylated cyclodextrin; dissolving the
reaction mixture
comprising the grafted-acylated cyclodextrin in acetone to make an acetone
solution;
precipitating the acetone solution in ice water to form a precipitate;
isolating the
70 precipitate; drying the precipitate to give a dried precipitate; and
reacting the dried
precipitate with an excess of pyrophosphoric acid to yield phosphorylated-
grafted-
acyiated cyclodextrin.
In another further aspect, the present invention is directed to a conjugate
comprising a peptide andlor a bioactive agent and a ph~osphorylated-grafted-
acylated
cyclodextrin, where the peptide and bioactive agent have at least one
interactive amino
group and the monophosphate group forms a linkage with the amino group.
The term "grafted" refers to a polyester graft oriiginating from a
heterocyclic
monomer, such as lactide, glycolide, trimethylene carbonate; andlor s-
caprolactone.
The term "absorbable" means that a water insoluble material such as a polymer
which undergoes chain dissociation in the biological environment to wafer
soluble by-
products as a function of time and leaves hardly any residue at the site of
implant or
administration.
The instant application denotes amino acids using the standard three letter
abbreviations known in the art, for example Ala = alanine.
The term "microparticle° as used herein, refers to the particles of
absorbable
polyester, which are preferably in essentially spherical form.
The term "monophosphate functionality" means that the polymer chain is
covalently linked to phosphoric acid by a single phosphate bond leaving two
additional
acidic -OH groups available for conjugation or neutraiizatio:n as depicted in
the following
structure: polyester-CHR-O-P(O)(OH)2, where R is, for example H or CH3.
The term "peptide" is meant to include peptides, polypeptides and proteins.
Examples of peptides include but are not limited to growth hormone releasing
peptide
(GHRP), leutenizing hormone-releasing hormone (LHRH), somatostatin, bombesin,
SUBSTITUTE SHEET (RULE 2fi)
CA 02339143 2001-O1-31
WO 00/09166 PCT/US99/18146
-6-
gastrin releasing peptide (GRP), calcitonin, bradykinin, gailanin, meianocyte
stimulating
hormone (MSH), growth hormone releasing factor (GRF), amylin, tachykinins,
secretin,
parathyroid hormone (PTH), encephalon, endothelin, calcitonin gene releasing
peptide
(CRP), neuromedins, parathyroid hormone related protein (PTHrP), glucagon,
neurotensin, adrenocorticothrophic hormone (ACTH), peptide YY (PYY), glucagon
releasing peptide (GLP), vasoactive intestinal peptide (VIP), pituitary
adenylate cyclase
activating peptide (PACAP), matilin, substance P, neuropeptide Y (NPY), TSH,
growth
hormone, erythropoietin, granulocyte-colony stimulating factor, granuiocyte-
macrophage-
colony stimulating factor, interferons, the LHRH analog p-Gllu-His-Trp-Ser-Tyr-
D-Trp-Leu-
Arg-Pro-Gly-NH2 (Peptide A), the somatostatin analog H-(3-.D-Nal-Cys-Tyr-D-Trp-
Lys-Val-
Cys-Thr-NH2 where the two Cys are bonded by a disulfide bond (Peptide B}, N-
hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2where
the two
Cys are bonded by a disulfide bond, or N-hydroxyethylpiperazinyl-ethyisulfonyl-
Phe-Cys-
Tyr-D-Trp-Lys-Abu-Cys-Thr-NHZ where the two Cys are bonded by a disulfide bond
95 (Peptide C), and analogs and fragments thereof or a pharmaceutically
acceptable salt
thereof.
The term "bioactive agent" is meant to include any chemical compound,
including
peptides, that can be administered to a patient for therapeutic or
prophylactic purposes
and, thus, includes pharmaceuticals.
The term "interactive amino group" refers to an annino group that is capable
of
chemically reacting with another chemical functionality, such as a hydroxy
group of a
monophosphate moiety.
The term "linkages" refers to chemical bonds, which can be ionic and/or
covalent
in nature, between the entities named.
The phrase °terminai monophosphate functionality per absorbable
polyester
chain" indicates that each end of the polyester chain c:an have a
monophosphate
functionality.
Members of the monophosphate family of polyesters which are miscible in
cyanoacrylate esters can be used as an acidic excipient in absorbable tissue
adhesive
compositions comprising alkoxyalkyl cyanoacrylates. The acidic functionality
of these
polyesters can stabilize the cyanoacrylate in the presence of trace amounts of
environmental contaminants that are basic in nature.
SUBSTITUTE SHEET (RULE 26)
CA 02339143 2001-O1-31
W4 00/09166 PCTlUS99/18146
-7-
The temp "low melting polyester" means that the po~fyester has a melting range
of
between about 25 °C to 120 °C.
The term °crystallinity" refers to the fraction of the solid that
exhibits 3-dimensional
order that is maintained until the material is heated to a temperature at or
above the
melting temperature where the material converts to a liquid.
Detailed Description
The present invention is directed to monophosphate analogues of several types
of
hydroxylic oligomers and polymers, which can be liquids, amorphous solids, or
crystalline
materials at room temperature. The free -P(O)(O~H)2 functionality of the
phosphorylated derivatives of the oligomeric and polymeric systems is capable
of
conjugating, sonically andlor covalently, with basic amine' groups of
bioactive agents
including peptides and proteins. The phospharylation can be conducted on
molten
polyester or solid microparticulate polyesters and pre-modified or in situ
modiiaed
polysaccharides, such as partially acylated cyclodextrins. The phosphoryiated
substrates
of this invention are used to form novel ionic conjugates with amino-acids,
pofypeptides,
and proteins or any organic compound that has at feast one available
interactive amine
group.
The hydroxylic oligomers and polymers that are the subject of this invention
include hydroxy terminated polyesters (HTPE) and acylated or alkylated
cyclodextrins.
The polyesters (HTPE) can be prepared by the ring opening polymerization of
lactones
(such as glycolide, lactide, E-caproiactone, p-dioxanone) andlor cyclic
carbonate (such
as trimethylene carbonate) in the presence of an inorganic or organometallic
catalyst
(such as stannous octoate) and a hydroxyl-bearing initiator (such as 1,6-
hexanediol, 1,3-
propanediol and diethylene glycol) under conditions that area commonly used in
the art for
ring opening polymerization (see Shalaby, S.W., et al., "Absorbable
Polyesters" in
Biomedical Polymers Designed to Degrade, Chapter 1, Shalaby, S.W. Ed. Hansen
Publ.,
NY 1994). The resulting polyesters, copoiyesters, or copolvester-carbonates
can be in
the form of a liquid, amorphous or highly crystalline material, having at
least one hydroxyl
group per polymeric chain. Highly crystalline solids of poiye;sters of this
invention can be
reduced in size to form microparticles having an average diameter of 0.1 to
100 microns.
Other hydroxylic oligomers and polymers include derivatives of
oiigosaccharide, such as
acylated or alkylated cyclodextrins, having at least one hydroxylic group per
molecule.
These derivatives can be phosphorylated directly or grafted with a polyester,
copofyester,
SUBSTITUTE SHEET (RULE 26')
CA 02339143 2001-O1-31
WD 00/09166 PCT/US99/18146
_g_
or copolyester-carbonate chains, such as those described above for the hydroxy-
terminated polyesters.
Conversion of the hydroxyl-bearing oligomers and polymers of the types
described herein is achieved by phosphoryiating the hydroxyl groups thereof,
using
reactive phosphoric acid derivatives, such as pyrophosphoric acid.
Stoichiometric or
excess amounts of the phosphorylating agent is used. The: reaction is carried
out with or
without an unreactive solvent and at a temperature ranging from about
10° C to 150° C
for a period of several minutes to several hours, depending on the chemica~!
structure of
the reacting substrate. At the conclusion of the reaction, the product is
fractionated to
remove any excess reagent and by-products. Upon u~~ing pyrophosphoric acid,
the
resulting reaction mixture is dissolved in a water-miscible solvent, such as
acetone. The
acetone solution is then added to stirring ice-water. This is. followed by
isolating the solid
phosphorylated product by centrifugation or ~Itration. After rinsing the
product sufficiently,
it is dried under reduced pressure. When crystalline microparticulate
hydroxylic
substrates are used, the reaction conditions can be adjusted to insure that
the
microparticles maintain their original dimensions after being phosphorylated.
The reaction
of the microparticulate can be conducted with or without tine use of a liquid
non-reactive
organic medium. Pyrophosphoric acid is a typical example of the reactive acid
derivatives
that can be used to insert-O-P(O)(OH)2functionaiity into the hydroxyl-bearing
substrate.
Examples of other phosphorylating agents that can be used in the present
invention
include methyl monophosphate, ethyl monophosphate and phenyl monophosphate.
To form conjugates of the different polymer monophosphates, the individual
polymer monophosphate is dissolved or suspended in a suitable medium "A", such
as
water or a mixture of water and acetonitrile, and allowed to interact with a
basic bioactive
agent present in an aqueous solution that is miscible in "A'''. Depending on
the chemistry
of the bioactive agent, a basic inorganic reagent may be required to present
the bioactive
agent in its free basic form. In case of a peptide salt, :such as a peptide
acetate, an
inorganic base, such as sodium bicarbonate, can be used to abstract the
acetate ions
from the peptide and allow its free base to conjugate, ionic:ally andlor
covaientiy, with the
monophosphate group of the oligomeric or polymeric substrates.
A microparticle of the present invention is made by micronizing a polymer by
initially grinding it using a Knife-grinder. The polymer i:> then micronized
in an Aljet
Micronizer using a pressurized dry nitrogen stream. The mean particle diameter
size is
SUBSTITUTE SHEET (RUt"E 2!s)
CA 02339143 2001-O1-31
a WO 00109166 PCTIUS99/18146
_g_
analyzed in a Malvern MastersizerlE using a volume distribution model and
20015 cS
silicone oil as dispersant.
The conjugate microparticles of this invention can be administered to a
patient via
administration routes well known to those of ordinary skill in the art, such
as parenteral
administration, oral administration or topical administration. Preferably, it
is administered
as a powder or a suspension via intranasai route or as an inhalant through the
pulmonary
system. When it is administered parenteraliy it is preferable that it is
administered as a
dispersion in an isotonic aqueous medium or in a non-aqueous, absorbable gel-
forming
liquid polyester as described in U.S. Patent No. 5;612,0.52, the contents of
which are
incorporated herein by reference. The formulations comprising conjugate
microparticles
of the present invention can also include a variety of optional components.
Such
components include, but are not limited to, surfactants, viscosity controlling
agents,
medicinal agents, cell growth modulators, dyes, complexing agents,
antioxidants, other
polymers such as carboxymethyl cellulose, gums such as guar gum, waxesloils
such as
castor oil, glycerol, dibutyl phthalate and di{2-ethylhexyl)phthalate and the
like. If used,
such optional components comprise from about 0.1 % to about 20%, preferably
from
about 0.5% to about 5°J° of the total formulation.
The effective dosages of a conjugate microparticles of the present invention
to be
administered to a patient can be determined by the attending physician or
veterinarian
and will be dependent upon the proper dosages contemplated for the peptide
andlor
bioactive agent conjugated in the microparticles. Such dosages will either be
known or
can be determined by one of ordinary skill in the art.
The disclosure of each of the references cited herein are incorporated herein
by
reference.
The following examples are provided for illustrative purposes and the
teachings
therein are not meant to limit the scope of the present invention.
Example 1
Preparation of a Hydroxy-Terminated (Polyester:
CEG-1 was made from caprolactone (137.3 g, 1.2()4 mole) and diethylene glycol
{12.7 g, 0.12 mole) using stannous octoate (Sigma Chemical Co., St. Louis,
MO), as a
catalyst, at 5000:1 mole ratio of monomerlcataiyst (1.3 mi of 0.2M toluene
solution}. The
flask was charged and set up with a mechanics! stirrer. 'The reactants were
heated for
about 12 hours at about 150° C under dry argon. The polymer was
isolated and purified
SUBSTITUTE SHEET (RULE 2fij
CA 02339143 2001-O1-31
WO 00109166 PCTlUS99/18146
-10-
by precipitating an acetone solution of the reaction mixture in ice water. The
resulting
polymer was isolated, dried, and then analyzed for identity composition,
molecular
weight, and thermal properties using IR, NMR, GPC, and DSC, respectively.
Unreacted
monomer was distilled under reduced pressure at about 12~D°C.
Substituting 1,3-propanediol for diethylene glycol at different
monomerlinitiator
ratios, a number of hydroxy terminated polymers, having .a range of molecular
weights,
were prepared according to the procedure described for Example 1. These
include CPD-
1 and CPD-2, which are based on E-caprolactone and 1,3-p~ropanediol.
Using a mixture of 70/30 !-lactide/glycolide, 8511;1 dl-Iactidelglycoiide,
70130 I-
lactidelglycoiide or 80120 I-lactide/dl-lactide, the respective copolymers,
denoted PDLG-1,
PDLG-2, PD-100, and PD-101, respectively; were produced substantially
according to
the procedure described for Example 1 under similar reaction conditions and
variable
amounts of 1,3-propanediol to achieve the desired molecular weights (Mn)
ranging from
2 to 20 kDa.
Example 2
Preparation of Phosphorylated Polyesters:
CEG-1-Phos-5 was made from CEG-1 (from Example 1) and pyrophosphoric acid
without the aid of a solvent using a 4:1 mole ratio of pyrophosphoric acid
(1.3 g) to CEG-
1 {5.0 g): The foregoing reaction mixture was allowed to react for about 80
minutes at
room temperature. The resulting product was dissolved in 30 ml acetone and
precipitated
in ice water. The polymer was isolated and dried under reduced pressure and
then
analyzed as described in Example 1. In addition, the phosphorous content was
determined by elemental analysis. The equivalent weight of the phosphorylated
product
was determined by acidimetry.
Following the foregoing procedure for making CEG-1-Phos-5, two other batches
of phosphoryiated CEG-1 were prepared, namely CEG-'1-Phos-6 and CEG-1-Phos-7.
Similarly, CPD-2 was phosphorylated to produce CPD-2-Phos-1 and copolymers,
PLDG-
1, PDLG-2, PD-100, and PD-101 to produce PLDG-1-Phoa-1, PDLG-1-Phos-1, PD-100-
Phos-1 and PD-101-Phos-1, respectively, all substantially <~ccording to the
procedure for
making CEG-1-Phos-5.
SUt3STtTUTE SHEET (RULE 26.)
CA 02339143 2001-O1-31
WO 00109166 PCTIUS99118146
-11-
Examt~ie 3
Preparation of Phosphoryiated Polyester/Polypeptide Conjugates:
CON-P3 was made from Peptide A and CEG-1-Phos-5A (another batch of CEG-
1-Phos-5}. Thus, CEG-1-Phos-5A (0.9974g) was dissolved in 10 mf of
acetonitrile. This
solution was filtered through a syringe filter in order to remove traces of
insoluble polymer
particles. Peptide A (199 mg) was dissolved in 2 ml of water. Based on the
acetate
content of the Peptide A, 25 mg of sodium carbonate was added to the polymer
solution
in acetonitrile to exchange with the acetate in the peptide. Peptide A
solution was then
added to the polymer solution dropwise. After the entire peptide solution was
added over
about a ten minute interval, the resulting solution was allowed to stir for
about 0.5 hour.
The solution was then precipitated into ice cold salt water and centrifuged to
collect the
product. The latter was rinsed with distilled water and recentrifuged. The
product was
dried under vacuum. The resulting conjugate was anaiyze~d for its peptide
content using
elemental analysis for nitrogen.
Following a similar procedure as described for Example 3, the conjugates
described in Table I were prepared from the designated individual peptides and
phosphorylated polyesters at the noted ratios and precipitation media (PM,
water or
isopropyl alcohol}.
Example 4
Preparation of Crystalline Hydroxy-Terminated Polydlycolide Microparticles:
PDGLY-1 was made as a solid crystalline material using about 25:1 mole ratio
of
gfycoiide to 1,3-propanediol. Glycoside (200 g, 1.724 mole) was melted in a
flame-dried
flask under argon and 1,3-propanediol (5.249 g, 69.1 mmole) was added.
Stannous
octoate (0.575 ml of 0.2M in toluene) was placed in the flask containing the
molten
reactants and the temperature was raised to about 1617 °C. After
approximately 30
minutes, the polymerization was concluded and the temperature was lowered to
about
110 °C. Unreacted monomer was removed by distillation at about 120
°C under reduced
pressure. The product was then ground and micronized as described hereinabove.
In a similar manner as the procedure for Example 4, PD-102 was made from a
1511 mixture of glycoside and 2,3-propanediol:
SUBSTITUTE SHEET (RULE 2,5)
CA 02339143 2001-O1-31
WO 00/09166 PCT/US99118146
-12-
Example 5
Preparation of Surface Phosphoryiated Polyglycolide Microparticles:
PDGLY-1-Phos-2 was made by melting 9.7 g of pyrophosphoric acid at about
60°
C and adding, while stirring under dry argon, 4.4 g of I'DGLY-1. The reaction
was
continued for about three hours at the same temperature. The product was
cooled to
about 10° C and then mixed with 20 mi of cold water. T'he mixture was
sonicated for
about 5 minutes, washed three times with water, and then dried under reduced
pressure.
The product was analyzed for its phosphorous content and Tm using elemental
analysis
and DSC, respectively.
In an analogous manner, PD-102 was converted to PD102-Phos1 substantially
according to the procedure for making PDGLY-1-Phos-2.
Example 6
Preparation of Typical Polypeptide Conjugates Using Phosphorylated
Poiygfycolide
Microparticles:
PICP3 was made from PDGLY1-Phos2 and Peptide B (50 mg) dissolved in 2 ml
of a 50:50 acetonitrile/water mixture. A 20 pl aliquot of the peptide solution
was removed
as a control sample. PDGLY1-Phos2 (502 mg) was added to the vial containing
the rest
of the peptide solution and sonicated for about eve minutes and then stirred
for about two
hours. The product was isolated by centrifugation and then dried under reduced
pressure. The supernatant liquid was analyzed by HPLC: to determine the amount
of
peptide bound to the powder. HPLC results indicated that 6.7%, by weight, of
peptide
was bound. The peptide content was found to be 7.2% by elemental analysis for
nitrogen.
In an analogous manner as the foregoing procedure, PD102-Phos1 was
conjugated with Peptide B to produce PICP-4.
Example 7
Preparation of Endo-Chain Carboxyiated 85/15 Poly(dl-lactide-co-glycoside) (TR-
100):
An 85!15 (molar) mixture of dl-lactide and glycolide was polymerized following
essentially the same procedure described in Example 1 but using L-tartaric
acid as the
initiator (at a molar ratio of 5011 lactone/tartaric acid) and stannous
octoate as a catalyst
(at a monomer to catalyst ratio of 500071 ).
Example 8
Phosphorylation of TR-100 to produce TR101-Phos2:
SU8ST1TUTE SHEET (RULE 26~)
CA 02339143 2001-O1-31
a WO 00/09166 PCT/US99/18146
-13-
The phosphorylation was conducted as described in Example 2, using a mixture
of TR-100 (15 g} and pyrophosphoric acid (1.244g).
Examale 9
Ionic Conjugation of TR100-Phos1 to Produce CON-P9, CON-P12, and CON-P15:
Using a similar procedure to that described for E>campie 3, Peptide B (373 mg}
was reacted with 1.5 g TR100-Phos1 to produce CON-P9. Similarly, CON-P12 was
prepared using Peptide A (400 mg) and TR100-Phos1 (2.5 g). In preparing CON-
P15,
cold 2-propanol was used as the precipitating medium producing a conjugate
based on
Peptide B (400 mg) and TR100-Phos1 (2.5g}.
Example 10
Preparation of a Phosphorylated Derivative of Gamma Cyclodextrin (GCD-Phos3}:
An aliquot of y-cyclodextrin (20.Og) was mixed in a predried flask with 46.23
g of
propionic anhydride and 16.46 g of pyrophosphoric acid in a dry nitrogen
environment:
The reactants were heated at about 45° C while being mixed for
approximately 0.5 hour.
The mixture was cooled and then precipitated into ice cold distilled water.
The product
was isolated and then dried under reduced pressure. Analysis revealed that the
material
has 0.43% phosphorous by weight and an equivalent weight of 1251.
Example 11
Preparation of a Typical Polypeptide Conjugate of Phoaphorylated y-
Cyclodextrin
Derivative:
A typical derivative such as GCD-Phos3 (1.7 g) vras conjugated with a peptide
{e.g., Peptide B, 300mg) as described for the conjugate preparation in Example
3, to
produce CONG-P100.
Example 12
Preparation of a Tissue Adhesive Composition:
The phosphorylated polyester from Example 2 (0.5 g) was dissolved in
methoxypropyl cyanoacrylate (0.5 g} and the resulting liquid composition was
stored at
room temperature in an untreated (not washed with acid) class vial for several
days and
showed no signs of polymerization (as indicated by no visible change in
viscosity).
Applying such tissue adhesive composition to a moist goat skin led to the
formation of a
compliant (flexible) tissue adhering film in about one minute.
SUBSTITUTE SHEET (RULE 213)
CA 02339143 2001-O1-31
WO 00/09166 PCT/US99/18146
-14-
Table i. Experimental Data for the Preparation of Typical Conjugates
Phosphorylated~ Phosphoryiated
Conjugate Polyester Peptide _Po~lyester/PeptidePM*
~
CON-P1 CEG1-PhosS B 1.ig1373mg H2O
CON-P7 CEG1-Phos6 B 2.0g1300mg H20
CON-P10 CEG1-Phos7 A 3.C)g/758mg H2O
CON-P11 CEG1-Phos7 A l.:ig/190mg IPA
CON-P13 CPD2-Phos1 A 3.0g/700mg H20
CON-P14 CPD2-Phos1 A 3.0g/500mg IPA
CON-P4 PDLG2-Phos1 B 1.;ig1373mg H20
B
CON-P5 PDLG2-Phos1 C 2.0g/333mg H20
B
CON-P6 PDLG2-Phos1 A 1.;ig/300mg H20
B
CON-P15 TR100-Phos1 A 2.;ig/400mg IPA
CON-P8 PD100-Phos1 B 1.;ig1373mg H20
CON-P16 PD101-Phos1 B 1.;ig1373mg H20
PIC-P3 PDGLY1-Phos2 B O.;ig/50mg N/A
PIC-P4 PD102-Phos1 B 0.;ig/50mg NIA
CONG-P100 GCD-Phos3 B 1.7g/300mg H2O
*PM= Precipitation medium
SU8ST1TUTE SHEET (RULE 28)
CA 02339143 2001-O1-31
WO 00/09166 PCTIUS99/18146
-15-
Table ii. Composition and Properties of Conjugates amd Their Precursors
Analytical Data
-
Polyester Yield GPC DSC Eq. Phos Peptide
Number % Mn Mw Tm Wt:' . %**
%
TR-100 81.2 8552 22,384 1333
PD-100 86.5 5205 16.3x103-- - -- --
PD-101 88.3 13.3x10318.6x103-- -- -- --
PD-102 99.1 __ _ -- _ __ __
CEG-1 96.0 2732 3134 47.57395
CPD-1 91.9 2732 3595 N/~~22,440
CPD-2 96.6 5788 8527 58.339,324
PDLG-2 93.8 10x103 17x103 ~ -- -- -
PDLG4-1 95.0 9388 13614
PDGLY-1 77.7 -- -- -- -- ~ --
Phosphorylated
NumberlPrecursor
Used
CPD2-Phos1ICPD-2 19.2 5376 24x103 5:3.6 745 0.85 --
TR100-Phos1/TR-10081.8 9067 29,656 -- 988 0.68
PD100-Phos1/PD-10089.0 6108 8776 3!x.3 1344 0.56
PDLG2- 97.2 8833 14 x103 46.2 2624 0.07 -
Phos1 B/PDLG-2
PD101-Phosl/PD-10170.0 8535 16,188 -- 1110 0.83
PD102-PhosllPD-10276.8 -- -- -- -- 0.98 --
CEG1-PhosSICEG-1 60.3 2926 3734 5:3.5 1339 1.11
CEG1-Phos6lCEG-1 69.6 4217 8825 4'1.4 960 2.11
CEG1-Phos7/CEG-1 52.0 4345 8593 -- 1020 1.85
PDLG1-PhosI/PDLG-78.1 8703 12,767 -- 2810 0.19
1
PDGLY1- 88.6 -- ~ -- -- 0.60
Phos2lPDGLY-1
GCD-Phos3IGCD 21.9 ~ -- 1251 0.43
SUBSTITUTE SHEET (RULE 2!3)
CA 02339143 2001-O1-31
WD 00/09166 PCTI(JS99118146
-16-
Table II (continued)
Analytical Data
~
Polyester YieldGPC DSC, Eq. Phos. Peptide
Number % Mn Mw Tm Wt.* % (%)**
Peptid e Numb erl or
PrecursU:>ed
CON-P9/TR100- 43.0 - B
Phos1 (10.96)
CON-P121TR100- 11.8 -- A
Phos 1 (21.4)
CON-P8/PD100- 73 54.4 B
Phos 1 (11.25)
CON-P4IPDLG2- 63.2 53.8 B
Phos1 B (4.9)
CON-PSIPDLG2- 73.5 48.0 C
Phos1 B (4.7)
CON-P6/PDLG2- 78.6 54.9 A
Phos1 B (4.8)
CON-P1/CEG1-PhosS 63.4 B
(18.5)
CON-P3/CEG1-PhosS 82.3 A
(12.8)
CON-P71CEG1-Phos6 33 47.8 B
( 12.66)
CON-P2/PDLG1- 62.4 B
Phos1 (5.4)
CON-P11/CEG1- 70.7 A
Phos7 (9.94)
CON-P10/CEG1- 6.8 A
Phos7 (5.69)
CON-P15/TR100- 72.4 -- A
Phos1 (6.2)
CON-P13/CPD2- 5.1 -- -- -- A
Phos1 (8.78)
CON-P14/CPD2- 75.1 -- -- 57.0 -- -- A
Phos1 (9.5)
SUBSTITUTE SHEET (RULE 26j
CA 02339143 2001-O1-31
WO 00/09166 PCT/US99118146
-17-
Table 11 (continued)
Analytical Data
Polyester Yield GPG DSG Eq. Wt.*Phos. Peptid
Number ! Mn Mw Tm % a (%)**
CON-P8/PD100- 73 - - 54.4 -- - B
Phos1 ( 11.25)
CON-P4/PLG2- 63.2 -- 53.8 -- B
Phos1 B (4.9)
CON-PS/PLG2- 73.5 -- -- 48.0 -- -- C
Phos1 B (4.7)
CON-P6lPLG2- 78.6 -- -- 54.9 - -- A
Phos 1 B (4.8)
CON-P16/PD101- 61.fi - - -- -- -- B
Phos1 (4.8}
P1C-P31PDGLY1- 74 -- -- __ __ __ g
Phos2 (7.2}
P(C-P4IPD102- 87.2 -- -- -- -- -- B
Phos1 (5.6)
CONG-P100/GCD- 70.3 -- -- -- -- -- B
Phos3 (4.3)
* Equivalent weight was determined by titration for acid ciroups
** Based on elemental analysis for nitrogen.
SUBSTITUTE SHEET (RULE 2,6)
CA 02339143 2001-O1-31
WO 00/09166 PCT/US99/18146
-18-
M s i ; s t : s
~
N
N C
1 i Z i O s s
N 1~ O
Its ,
r O s i = O = i r
O N
O
s
O i ~ V C O i
0D
dlC d. O r- O
0
t~?td ~ _ ~ O f ~ 0
~n u~ ao ~r ~t
QI N O
~- N 1C!
v
o C ~ i i ~ N = ~ r
01 M G! 0D
O N
O ~ ~ ~ ~ V ~' i I 1
C7
y, CO O tt~
dy O M r 17 ~ M M ~ s t
~
m ~, tn a0 t~. v-
O N ~ ~ ~ M C9 d' i i
N - ~ - _
~ O
~ D N C7 ~ M M dJ eh I i
m
H
Wit c
IQ ~. ; '~ y
M ,", eh N
M
V m O . ~C N M N CV r'? tD
r
'D
G
t~ et tl~
V
.r ~ ~ ' M et 01
O O C ~7
D
D d' N A N ~'rl ~
~,f/>>, C1 N f~
M , Q ~O CO N ~.
,r
.t~C D ~fiN ~- N ~ ~ N , r
r- N7
m s
m ~
O
tt7 ..., 0 ... ~ ~ C N
G
d '" 0 'd, N C7 N 00 ,
0 N
n v m ~ ~ v Q v m v V v v m W m W
. d ... ..
1r
a a a a a a a a
, , , , , ,
U U U U V
V U U U
SUBSTITUTE SHEET (RUE.E 2,5~
CA 02339143 2001-O1-31
WO X109166 PCTIUS99/18146
-19-
M
s 1 i i i i Z i
N
i i 1 Z ; 1 1 1
r-
V i ~ i 1 i i i 1
O
Q
~
M i ~ I i I i i i
W
m d
a a
m ~ of
C C
." ~i s o ~ I s s ; s I
o .-.
,.- .
t0 ~ N
1 . o r 1 1 s 1 1
5.
O
1 ~ I i
a
~ ; 1
ch
m
m
oc cC ~,
~,
i ~ ON 1 1
~ ~ - ~ _
w Z ~ DN ~ t 1
E E
~' ~'
M
m r ~
O t I 1
C
a w
f%? wj H~
w .- ~ O can i ~ I
v ~
~
t/>f ~ ~ ~. O 00 fD
f
v ~ ~ ~ O M N ~ i
~N ~ tt7
_- ~
m = m
~ ~
~ f,~ GL...p~ ~ L t~ N O
~ m O
V a ~
v Q v ~ d Q 'Q Q Q d m
v ~ v ~ ~ v v
~r
p .Crm.. ~ N l'~i ~ ICs iLi
a n. H ~ a a a a a a
V U U U U U U U U
V
SUBSTITUTE SHEET (RULE 2!i)
CA 02339143 2001-O1-31
. ~ WO 00!09166 PCT/US99/18146
-20
c
0
»..
c
U
i
i = i Q
N
a
i = i =
~f
* C_
~ i i I ~
0:o i r r ~
a
W
r s
a
.~
.
~
~r' E
3
m a~
L
c~ 1 a
co ~ ~'
r m
o
V L~HM N ~ ~
c E o
N ~ ~ CV .~N.. ~ N
V N '_ ~ 'CN
S M C
CV tn .~ G
v ~ ~
3 ~
m c N
0 3
.c
_ ~. _
a m m '-m ' ~ ~ o
~ :~ ~ 3 E ~o
$ ~ c
U .d. ' o m
o U O m 'v_
c~ a a U a ~ ~
E ,,
o
~ :
SUBSTITUTE SHEET (RULE 2:6)
